Asia Pacific Urinalysis Market Outlook, 2030

The Asia Pacific urinalysis market has developed into one of the most dynamic and promising areas within the global diagnostics sector, driven by increasing healthcare awareness, a growing prevalence of chronic and infectious diseases, rapid urban development, and innovations in diagnostic solutions. From 2021 to 2031, the market is anticipated to see strong growth due to the enhancement of healthcare infrastructure, an expanding middle-class population, and a rise in demand for point-of-care testing in both urban and rural environments. Urinalysis—an essential, non-invasive, and cost-efficient diagnostic tool—is extensively utilized in identifying a wide range of conditions such as urinary tract infections (UTIs), diabetes, kidney and liver diseases, as well as metabolic disorders, all of which are becoming more common in countries throughout the Asia Pacific region. The area is experiencing a significant increase in non-communicable diseases like diabetes and hypertension, which are closely associated with kidney issues and necessitate regular urinalysis for their monitoring and management. As per the International Diabetes Federation, Asia represents more than 60% of the worldwide diabetic populace, with nations like China and India carrying a substantial burden. Furthermore, age-related ailments and the growing elderly population contribute to a rising occurrence of kidney and liver dysfunction, thereby increasing the demand for early and consistent urine testing. Governments in nations such as Japan, South Korea, and Australia have been proactive in promoting preventive healthcare, while emerging economies like India, China, Indonesia, and Vietnam are investing in enhancing their public healthcare frameworks and diagnostic infrastructure.

Asia Pacific urinalysis market will grow by 7.7% annually with a total addressable market cap of $ 10,873.5 million over 2022-2031. Technological advancement is playing a key role in transforming the urinalysis market, particularly in urban areas where the adoption of digital health is on the rise. Automated urine analyzers, the incorporation of artificial intelligence (AI) in diagnostics, and the increasing use of smartphone-compatible point-of-care devices are facilitating faster and more precise testing, thereby minimizing the necessity for manual intervention and errors. The spread of affordable test kits and dipsticks also renders urinalysis accessible in rural and under-resourced communities, enhancing equitable healthcare provision. Moreover, growing awareness regarding personal health, the rising penetration of medical insurance, and a post-pandemic emphasis on preventive testing are boosting regular health check-ups and home-based diagnostics, further propelling market demand. Leading companies in the Asia Pacific urinalysis market include global leaders such as Siemens Healthineers, Roche Diagnostics, Sysmex Corporation, and Beckman Coulter, along with numerous regional and local manufacturers that provide cost-effective, high-volume solutions. These firms are broadening their presence through collaborations, mergers, and distribution networks to meet the increasing demand in the region.

The urinalysis market in the Asia Pacific is influenced by the varied healthcare environments of several important nations, including China, India, Japan, South Korea, Australia, and Southeast Asian countries such as Indonesia, Thailand, and Vietnam. Among these, China possesses the largest market share, owing to its extensive population, escalating chronic disease prevalence, and strong emphasis on healthcare modernization. The government’s investment in health infrastructure and the broad application of health screening initiatives have spurred demand for regular diagnostic tools like urinalysis. Likewise, India is experiencing swift market growth, motivated by a significant occurrence of diabetes and kidney disorders, increasing urban development, and rising awareness of preventive diagnostics. The healthcare initiatives from the Indian government, along with the private sector's contribution to enhancing diagnostic accessibility in semi-urban and rural regions, are driving notable growth. Japan and South Korea represent established markets with advanced healthcare systems and high levels of adoption for automated diagnostic technologies. These nations are at the forefront regarding technological advancements, integrating AI, digital practices, and point-of-care devices into clinical operations. Australia also plays a vital role, emphasizing decentralized healthcare and extensive diagnostic access throughout both urban and remote areas. In Southeast Asia, countries such as Indonesia, Thailand, and Vietnam are emerging as promising markets due to growing healthcare investments, increasing disease awareness, and broader health insurance coverage. These countries are prioritizing the enhancement of laboratory infrastructure and the advancement of healthcare services in rural areas.

By Product Type, the Asia Pacific urinalysis market is divided into Instruments and Consumables. Within instruments, Automated Analyzers are highly sought after in hospitals and laboratories for their efficiency and capacity to manage high test volumes. Semi-automated Analyzers continue to be significant in mid-tier facilities, providing cost-effective options in areas with limited resources. Point-of-Care (PoC) Analyzers are experiencing increased adoption in clinics and homecare due to their portability and quick results. The consumables segment is thriving, led by Reagents and Kits, which are crucial for reliable testing across various disease categories. Dipsticks remain the preferred choice for routine testing due to their affordability and user-friendliness, particularly in rural regions. Disposables such as containers and accessories are being utilized more frequently in both institutional and residential settings. As healthcare systems throughout Asia evolve and focus on decentralized diagnostics, demand for all these product segments is anticipated to grow steadily from 2021 to 2031. By Test Type, the market encompasses Biochemical Tests, Pregnancy and Fertility Tests, and Sediment Tests. Biochemical tests hold the largest market share owing to their adaptability in identifying glucose, proteins, bilirubin, ketones, and other critical markers related to diabetes, liver, and kidney ailments. The rise in chronic diseases in populous nations like India and China has heightened the demand for these tests in hospitals and home environments. Pregnancy and fertility tests are seeing robust adoption, particularly in homecare, as awareness surrounding reproductive health increases. These tests are readily available over the counter and are more frequently used in family planning and prenatal care. Sediment tests, necessitating microscopy, are essential for identifying urinary tract infections, hematuria, and crystals, typically conducted in laboratories and tertiary hospitals. With enhanced access to healthcare and investment in diagnostic facilities, the demand for all test types is predicted to increase significantly until 2031.

By Applications, the Asia Pacific urinalysis market is classified into Pregnancy and Fertility, Urinary Tract Infections (UTI), Diabetes, Kidney Diseases, Liver Diseases, and Other Applications. UTIs continue to be a primary application due to high occurrence rates, particularly among women and the elderly, necessitating prompt, precise diagnosis. The management of Diabetes substantially propels the market, given Asia’s large population of diabetics requiring routine urine-based glucose and ketone tracking. Pregnancy and fertility applications are gaining traction, especially with increasing awareness of maternal health and the accessibility of home test kits. Kidney and liver diseases, which are becoming more prevalent due to aging and lifestyle changes, require urinalysis for early diagnosis and disease management. Other applications encompass drug testing, general health assessments, and monitoring systemic infections. The expanding landscape of diagnostic applications and a growing focus on preventive healthcare is expected to drive steady growth across all urinalysis use cases by 2031. By End User, the Asia Pacific urinalysis market encompasses Hospitals and Clinics, Diagnostic Laboratories, Home Care Settings, and Research Laboratories and Institutes. Hospitals and clinics lead the market, acting as main hubs for managing both acute and chronic diseases while providing both manual and automated testing services. Diagnostic laboratories, especially those in urban areas, play a crucial role, offering high-volume and rapid turnaround capabilities enhanced by automated systems. The home care segment is experiencing swift growth, propelled by a trend towards self-testing, particularly for pregnancy, diabetes, and UTI monitoring, aided by cost-effective, user-friendly devices. Research laboratories and institutes are increasingly utilizing urinalysis for clinical trials, biomarker research, and drug development projects, notably in more advanced nations such as Japan and South Korea. With the growth of public health initiatives and increasing demand for decentralized and tailored care, all end-user segments are projected to aid in the market growth of the region through 2031.



Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Asia Pacific Urinalysis Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

Based on Product Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Instruments
• Automated Analyzer
• Semi-automated Analyzer
• Point-of-Care Analyzer
• Consumables
• Reagents & Kits
• Dipsticks
• Disposables

Based on Test Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Biochemical Test
• Pregnancy & Fertility Test
• Sediment Test

By Applications, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Pregnancy & Fertility
• Urinary Tract Infections (UTI)
• Diabetes
• Kidney Diseases
• Liver Diseases
• Other Applications

By End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Hospitals and Clinics
• Diagnostic Laboratories
• Home Care Settings
• Research Laboratories & Institutes

The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and listing out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, annual report of companies, analyzing the government generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducted trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers in regional aspects, tier aspects, age group, and gender. Once we have primary data with us we have started verifying the details obtained from secondary sources.

Intended audience
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to agriculture industry, government bodies and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.